Pharmacogenetics and oral antithrombotic drugs.

Abstract excerpt

Warfarin and other oral vitamin K antagonists (VKAs) have been the primary pharmacologic options with well-established efficacy data in high-risk patient populations. Warfarin dose requirements to achieve therapeutic anticoagulation are highly variable. This variability in response results in increased risk for adverse events, including thromboembolism and bleeding. Genetic variants in CYP2C9 and VKORC1 have been...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Administration, Oral
• Share to Anticoagulants
• Share to Fibrinolytic Agents